News

                        Array
(
    [0] => stdClass Object
        (
            [id] => 1290
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => b7db2d93bf200e7e5731.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-03-18
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-03-18 15:58:16
            [updated_time] => 2025-03-18 16:03:00
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => https://gentis.com.vn/tin-tuc-c4/gentis-gioi-thieu-xet-nghiem-pgt-next-va-pgt-upgrade-tai-benh-vien-buu-dien-d1290
            [title] => GENTIS introduces 2 new PGT test packages at Hospital of Post and Telecommunications
            [description] => On the afternoon of March 6, GENTIS coordinated with the Post Office Hospital to organize a seminar introducing two newly launched PGT testing packages: PGT NEXT and PGT UPGRADE. Throughout the seminar, GENTIS representatives discussed and answered questions from doctors at the Post Office Hospital about these new genetic testing packages.
            [content] => 
Attending the seminar, on behalf of the IVF Center, the Post Office Hospital had the presence of Master. Doctor Bach Huy Anh (Deputy Director), Master. Doctor Chu Thi Huong, Doctor CKI. Kieu Duc Ty and doctors of the department. Representing GENTIS, there was the participation of Mr. Nguyen Quang Vinh (Director of Testing Center) and Mr. Nguyen Van Huynh (Leader of R&D).
Mr. Vinh and Mr. Huynh gave a detailed introduction to the two test packages PGT NEXT and PGT UPGRADE of GENTIS. Sharing with the doctors of the HTSS Center - Post Office Hospital, Mr. Huynh emphasized the technological breakthrough of both new PGT tests.

Accordingly, the PGT NEXT test is a test that can detect haploid/polyploid embryos. According to statistics during the research process at GENTIS: "Haploid/polyploid abnormalities occur in 1-3% of all pregnancies and triploidy accounts for 15-18% of miscarriages." Therefore, detecting haploid/polyploid embryos is highly significant in increasing the success rate of IVF.
In addition, PGT NEXT also supports and complements PGT-A/SR, helping to detect polyploid embryos and identify embryos with normal diploid chromosome sets, even in abnormally fertilized embryos (e.g., 0PN, 1PN, or 2.1/3PN).
This test can be extended to patients with a history of polyploidy, molar pregnancy, and miscarriage after IVF combined with traditional PGT-A, increasing the number of embryos that can be transferred from abnormally fertilized zygotes (0PN, 1PN, or 2.1/3PN). The implementation process combines whole genome sequencing NGS (Low-pass sequencing) with targeted SNP sequencing to detect polyploidy.

For PGT UPGRADE, this is a test to detect embryos carrying balanced translocations. "Balanced translocation is the phenomenon of exchanging DNA segments between non-homologous chromosomes without increasing or decreasing genetic material at the breakpoints. In balanced translocation, there are also two types: Reciprocal translocation and Robertsonian translocation."
The PGT UPGRADE test is indicated for couples with a history of recurrent miscarriage, a family history of chromosomal abnormalities, or spouses carrying balanced translocations who do not want to pass them on to the next generation. The implementation process combines whole genome sequencing NGS (Low-pass sequencing) with targeted SNP sequencing to detect embryos carrying balanced translocations.
The outstanding advantage of the PGT NEXT and PGT UPGRADE tests is the use of specialized bioinformatics software optimized specifically for the Vietnamese population. Therefore, these two tests not only help detect genetic abnormalities but also help reduce the risk of miscarriage, increase the success rate of in vitro fertilization (IVF) and help select healthy embryos to be placed in the uterus.

At the end of the presentation, doctors at the Post Office Hospital asked many questions about PGT NEXT and PGT UPGRADE, specifically: "Is 18% of the total number of embryos the proportion of euploid embryos carrying balanced translocations?", "With this new technology, is the cost of performing PGT UPGRADE much higher than the cost of performing PGT-A?". Thanks to the detailed answers of the GENTIS representative, the doctors had a clearer view and could visualize the future development of the PGT NEXT and PGT UPGRADE tests.

The seminar took place in a very exciting atmosphere and received a lot of attention and positive feedback from the participating doctors. Master, Doctor Bach Huy Anh shared: "Thank you GENTIS for coming to our hospital today and updating new products that are extremely meaningful and highly practical. For me personally, the PGT UPGRADE test has a high humanitarian significance, helping couples with balanced translocation genes prevent the possibility of passing it on to future generations. I believe that in the future, these two tests will greatly support infertile couples with multiple miscarriages, helping them reach their dream of becoming parents."
            [content_more] => 
            [meta_title] => GENTIS introduces 2 new PGT test packages at Hospital of Post and Telecommunications
            [meta_description] => On the afternoon of March 6, GENTIS coordinated with the Post Office Hospital to organize a seminar introducing PGT NEXT and PGT UPGRADE.
            [meta_keyword] => gentis,Pgtnext,Pgtupgrade
            [thumbnail_alt] => 
            [post_id] => 1290
            [category_id] => 4
        )

    [1] => stdClass Object
        (
            [id] => 1289
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => f6d5e56ee8de598000cf.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-03-18
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-03-18 14:29:48
            [updated_time] => 2025-03-18 14:36:21
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => https://gentis.com.vn/tin-tuc-c4/gentis-tai-tro-hoi-nghi-phoi-hoc-lam-sang-nam-2025-cec-lan-thu-6-d1289
            [title] => GENTIS sponsors Clinical Embryology Conference 2025 - CEC 6
            [description] => Time: 22 - 23/03/2025
Location: Wyndham Legend Halong Hotel, No. 12 Bai Chay, Ha Long City, Quang Ninh
            [content] => 
On March 22-23, 2025, Clinical Embryology Conference 2025 - organized by the Ho Chi Minh City Association of Reproductive Endocrinology and Infertility (HOSREM) will be held at Wyndham Legend Halong Hotel, No. 12 Bai Chay, Ha Long City, Quang Ninh. GENTIS Genetic Testing Service Joint Stock Company is honored to be a sponsor of the conference.
The 6th CEC is a specialized conference on clinical embryology and new technical and technological applications in assisted reproduction. This year's conference will update knowledge, technical trends, technology, and new protocols in assisted reproductive techniques.
At the exhibition booth at the conference, GENTIS will focus on introducing solutions in genetic screening and diagnosis in the field of assisted reproduction, especially 2 new PGT test packages: PGT NEXT and PGT UPGRADE

PGT UPGRADE
PGT UPGRADE is a pre-implantation genetic analysis test that can detect aneuploidy on 24 chromosomes, additional abnormalities, chromosomal deletions with a size of over 5 Mb, especially capable of detecting embryos carrying balanced translocations inherited from the parents. Chromosomal translocations are structural abnormalities of chromosomes caused by the rearrangement of large segments between non-homologous chromosomes. There are two types of translocations: balanced (no loss of genetic material) and unbalanced (loss or extra genetic material, such as aneuploidy). When both the father and mother carry balanced translocations, approximately 60% of gametes will carry unbalanced translocations, leading to embryos with chromosomal abnormalities. This is also a common cause of repeated implantation failure, recurrent miscarriage, and birth defects. PGT UPGRADE test helps to select euploid embryos for parents carrying balanced translocations to increase the chance of having a healthy baby. In addition, PGT UPGRADE also supports providing genetic information for the embryo selection process before embryo transfer.
Performing PGTest testing can select genetically good quality embryos to increase the chance of pregnancy when performing in vitro fertilization (IVF), helping to increase the chance of the child being born healthy, without the screened genetic abnormalities.
Detection range:
- Aneuploidy of all 24 chromosomes.
- Chromosome structural abnormalities (addition, deletion) with a size of over 5 Mb.
- Detecting embryos carrying balanced genetic translocations from parents.
Method: Next-generation sequencing NGS (Illumina) and analyzing sequencing results using specialized bioinformatics software.
Samples used:
- Parental samples (2-3 ml whole blood in EDTA anticoagulant tube) and balanced translocation test results.
- Embryo biopsy sample on day 5.
Time to return results: 12 – 14 days.
PGT NEXT
PGT NEXT is a pre-implantation genetic analysis test that can detect aneuploidy on 24 chromosomes, chromosomal abnormalities, and chromosomal deletions. It can also detect embryos with polyploidy or haploidy. This helps avoid transferring polyploid/haploidy abnormal embryos, and avoid wasting euploid embryos with fertilization abnormalities (0PN, 1PN, and 2.1/3PN). In addition, the PGT UPGRADE test also supports the provision of genetic information for embryo selection before embryo transfer. The combination of NGS whole genome sequencing with SNP analysis improves the resolution of genetic screening for polyploidy.This method allows for the identification of haploid and polyploid chromosome sets, increasing the number of healthy euploid embryos available for transfer by accurately detecting true diploid embryos among abnormally fertilized embryos (0PN, 1PN, 2.1PN, 3PN). Additionally, SNP analysis ensures precise identification of whether the tested embryo is genetically related to other embryos in the same cohort, thereby reducing the risk of sample mix-ups due to procedural or handling errors.
Detection range:
- Aneuploidy of all 24 chromosomes.
- Chromosomal structural abnormalities (addition, deletion).
- Detection of embryos with polyploidy or haploidy.
Method: Whole genome sequencing and sequencing of target markers on the next generation sequencing machine NGS.
Samples used: Embryo biopsy sample on day 5.
Time to return results: 3 – 4 weeks.
Not only that, GENTIS's booth also provides the latest genetic testing documents in the field of assisted reproduction and prepares many attractive gifts of gratitude to the delegates
️We respectfully invite doctors/ embryologists/ experts to visit GENTIS's booth to update the most modern and advanced pre-implantation genetic screening testing solutions, serving the needs of better medical examination and treatment of Vietnamese people.
            [content_more] => 
            [meta_title] => GENTIS sponsors Clinical Embryology Conference 2025 - CEC 6
            [meta_description] => On March 22-23, 2025, Clinical Embryology Conference 2025 - organized by the Ho Chi Minh City Association of Reproductive Endocrinology and Infertility (HOSREM) will be held at Wyndham Legend Halong Hotel, No. 12 Bai Chay, Ha Long City, Quang Ninh.
            [meta_keyword] => gentis,Cec
            [thumbnail_alt] => 
            [post_id] => 1289
            [category_id] => 4
        )

    [2] => stdClass Object
        (
            [id] => 1287
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 90de80bcd93e6860312f.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-03-14
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-03-15 08:33:23
            [updated_time] => 2025-03-17 16:01:31
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => https://gentis.com.vn/tin-tuc-c4/gentis-gioi-thieu-xet-nghiem-fish-va-2-goi-xet-nghiem-pgt-moi-tai-bv-san-nhi-phu-tho-d1287
            [title] => GENTIS introduces FISH test and 2 new PGT test packages at Phu Tho Obstetrics and Pediatrics Hospital
            [description] => On the afternoon of March 12, GENTIS coordinated with Phu Tho Obstetrics and Pediatrics Hospital to organize a seminar introducing the FISH test and two newly launched PGT test packages: PGT NEXT and PGT UPGRADE. At the seminar, GENTIS representatives discussed and answered questions from doctors at Phu Tho Obstetrics and Pediatrics Hospital about these new genetic test packages.
            [content] => 
Attending the seminar, on behalf of the Center for Reproductive Support, Phu Tho Obstetrics and Pediatrics Hospital, there was the presence of Dr. Doan Trung Kien (Director), Dr. Nguyen Thi Mai (Deputy Director), Dr. Le Ngoc Tue Nhi (Head of IVF Lab) and doctors of the department. Representing GENTIS, there were Mr. Nguyen Van Huynh (Head of R&D Group) and Dr. Vu Thu Huong.
At the seminar, Dr. Vu Thu Huong gave a detailed presentation on FISH, the process, principles and values ​​that this test brings. In addition, Mr. Nguyen Van Huynh also introduced and presented in detail about the two PGT NEXT and PGT UPGRADE test packages of GENTIS. One of the highlights of the seminar was the discussion about the benefits and technology applied to the two newly launched PGT products of GENTIS. According to Mr. Nguyen Van Huynh, thanks to the use of specialized bioinformatics software optimized for the Vietnamese population, this test not only helps detect genetic abnormalities but also helps reduce the risk of miscarriage, increase the success rate of in vitro fertilization (IVF) and help select healthy embryos to place in the uterus.
PGT testing helps couples avoid difficult situations, such as facing an unhealthy pregnancy or the risk of giving birth to a child with a serious genetic disease. Especially for older couples or couples with a history of genetic disease, PGT is an effective solution, helping to screen and select healthy embryos, thereby increasing the chance of having a safe and healthy child.
During the seminar, doctors at Phu Tho Obstetrics and Pediatrics Hospital asked many questions about FISH testing as well as PGT NEXT and PGT UPGRADE: "Can embryonic cells after FISH be used for other tests?", "The time to return results of PGT NEXT seems a bit long, can it be reduced in the future?". Accordingly, Mr. Nguyen Van Huynh and Dr. Vu Thu Huong gave extremely detailed answers, delving into the issues that doctors were still wondering about. This provided doctors with a clearer understanding of the future development of FISH, PGT NEXT and PGT UPGRADE tests at GENTIS.
The seminar took place in an engaging and dynamic atmosphere and received a lot of attention and positive feedback from the participating doctors. Dr. Doan Xuan Kien said: "I am very grateful and appreciate the presence of GENTIS today, thank you for organizing such a meaningful and practical seminar, helping doctors to update new knowledge about FISH testing, as well as better understand the breakthrough and necessity of applying PGT NEXT, PGT UPGRADE in pre-embryo genetic testing technology. These tests are not only a great step forward in medicine but also bring a new ray of hope to couples on the journey to find their beloved children".
Hopefully after the seminar, GENTIS and Phu Tho Maternity and Pediatrics Hospital will have more opportunities to cooperate for the development of both units!
            [content_more] => 
            [meta_title] => GENTIS introduces FISH test and 2 new PGT test packages at Phu Tho Obstetrics and Pediatrics Hospita
            [meta_description] => GENTIS coordinated with Phu Tho Obstetrics and Pediatrics Hospital to organize a seminar introducing the FISH test and PGT NEXT, PGT UPGRADE. 
            [meta_keyword] => gentis,Pgt,Pgtnext,Pgtupgrade
            [thumbnail_alt] => 
            [post_id] => 1287
            [category_id] => 4
        )

    [3] => stdClass Object
        (
            [id] => 1286
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => dsc02895.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-03-14
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-03-14 09:09:13
            [updated_time] => 2025-03-14 15:58:11
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => https://gentis.com.vn/tin-tuc-c4/gentis-tiep-don-doan-chuyen-gia-illumina-den-tham-quan-va-lam-viec-d1286
            [title] => GENTIS welcomes Illumina experts to visit and work
            [description] => On March 13, GENTIS was honored to welcome Illumina experts to visit and work in Hanoi. The delegation was led by Ms. Katie Battese Ellis - Senior Director, Medical Affairs of Illumina in charge of several countries in the APAC region, along with Illumina experts in Vietnam.
            [content] => 

GENTIS representatives welcomed the delegation with Mr. Do Manh Ha - General Director, Dr. Pham Dinh Minh - Director of R&D and related departments/offices. At the meeting, the delegation visited the office area, the international standard GENTIS Eurofins Laboratory and shared experiences and genetic knowledge with GENTIS. Accordingly, Ms. Katie highly appreciated the design, equipment, and machinery of GENTIS's lab and hoped to have more opportunities to accompany the company.

GENTIS believes that Illumina - the world's leading Biotechnology group in human health and genomics, a pioneer in innovating the future of precision health, will be a reliable and long-term partner, helping GENTIS develop rapidly and sustainably in the future! As a partner of Illumina in Vietnam, GENTIS will continue to conquer new applications and technologies to bring more value to customers and patients, with the ambition to pioneer becoming a unit with a comprehensive genetic ecosystem.

With 15 years of experience in building and operating a modern Genetic Testing Center, GENTIS is ready to welcome domestic and foreign medical units to visit, share, exchange experiences, and learn to improve the quality of testing to serve doctors in accurate diagnosis, effective treatment for patients, as well as better health care for people every day. GENTIS Hanoi is proud to own a modern LAB, surpassing many strict domestic and international quality standards: ​

Area up to 2,000m2
Located in the city center, convenient transportation
GENTIS Eurofins laboratory system meets ISO 9001:2015, ISO 15189:2022, ISO 13485:2016, ISO/IEC 27001:2022 standards and aims for CAP standards
Leading technology equipment from the US, Europe, Korea... such as: New generation sequencing NGS; iScan system; Realtime PCR technique; Sanger sequencing; Flow Cytometry Technique
Process of testing in a professional lab, ensuring accuracy
Highly specialized R&D team
Technical team for sample collection and testing are well-trained and specialized

            [content_more] => 
            [meta_title] => GENTIS welcomes Illumina experts to visit and work
            [meta_description] => On March 13, GENTIS was honored to welcome Illumina experts to visit and work in Hanoi. The delegation was led by Ms. Katie Battese Ellis
            [meta_keyword] => gentis,Illumina
            [thumbnail_alt] => 
            [post_id] => 1286
            [category_id] => 4
        )

    [4] => stdClass Object
        (
            [id] => 1284
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 696d27fcb92a0874513b.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-03-11
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-03-11 15:58:39
            [updated_time] => 2025-03-15 10:52:37
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => https://gentis.com.vn/tin-tuc-c4/tien-si-pham-dinh-minh-bao-cao-tai-hoi-nghi-y-sinh-hoc-tzu-chi-academia-sinica-lan-thu-7-d1284
            [title] => Dr. Pham Dinh Minh reported at the 7th Tzu Chi - Academia Sinica Biomedical Conference
            [description] => On March 8, 2025, Dr. Pham Dinh Minh (Director of R&D GENTIS - Director of GENTIS Genetic Counseling Center) gave a report at the 7th Tzu Chi - Academia Sinica Biomedical Conference at Tzu Chi University, Hualien, Taiwan. The report was on the topic: "Development and application of AI/Bioinformatics in genetic and genomic testing in Vietnam".
            [content] => 
The 7th Tzu Chi - Academia Sinica Biomedical Conference
The 7th Tzu Chi - Academia Sinica Biomedical Conference 2025 was held at Tzu Chi University, Hualien City, Taiwan. This year's conference focused on the theme of “Applications of AI in Biomedical Research” and “Multidisciplinary Perspectives in Biomedical Research & Therapy”.
Dr. Pham Dinh Minh - Director of R&D GENTIS (standing in the middle) with experts at Tzu Chi University
The conference brings together leading scientists and experts in the field of biomedical science in the world from the US, Japan, Korea, Vietnam, Thailand, Indonesia, Philippines, etc. The conference provides delegates as well as the community developing artificial intelligence in medicine in general, biomedicine in particular, with the latest research and development as well as the market in the field of research and application of AI.
Report by Dr. Pham Dinh Minh at the 7th Tzu Chi - Academia Sinica Biomedical Conference
The application of genetic and genomic testing is booming in the healthcare sector in Vietnam. Recently, we have witnessed the rapid application of tests in many healthcare areas, such as reproductive health, obstetrics and gynecology, newborn screening, cancer and cardiovascular diseases…
As we know, the development of AI has attracted many people, especially those working in the field of research and development. For the general community, the development of AI tools such as China's Deepseek or xAI's Grok has greatly changed the development as well as the application in social life.

Dr. Minh presented the report "Development and application of AI/Bioinformatics in genetic and genomic testing in Vietnam"
In the medical field, although still very new, AI has also been developed. In Vietnam, there are very good potentials, especially the amount of data, the huge amount of data related to health and testing. In particular, GENTIS is one of the large testing units and has a huge amount of data in Vietnam about genetic testing, gene testing. This is one of the advantages of GENTIS to be able to apply to develop as well as research AI in the testing field.
At the 7th Tzu Chi - Academia Sinica Biomedical Conference, the report on the topic "Development and application of AI/Bioinformatics in genetic and gene testing in Vietnam" by Dr. Pham Dinh Minh (Director of R&D GENTIS - Director of GENTIS Genetic Counseling Center) attracted the attention of many attending experts. In the report, Dr. Pham Dinh Minh shared research and applications of AI and bioinformatics in genetic and gene testing, aiming to develop new tests and improve the quality of testing. Especially genetic testing in pre-implantation embryo screening, genetic testing in non-invasive prenatal screening as well as other genetic and gene testing.

Dr. Minh received a certificate at the 7th Tzu Chi - Academia Sinica Biomedical Conference
In addition, the report also provides the conference, as well as the Asia-Pacific scientific community, with information on the development, research, and application of AI, as well as bioinformatics in Vietnam in general and the medical, genetic and genetic testing fields in Vietnam in particular.
GENTIS applies AI/bioinformatics software in genetic research and testing
“Developing AI applications/bioinformatics software is one of the key, main areas that GENTIS is oriented to develop in the coming time. GENTIS is looking forward to finding opportunities to cooperate with partners as well as developing further, researching and developing the latest directions of artificial intelligence applications as well as applying AI technology in genetic testing, genetic testing to bring new and improved tests, improving the quality of current tests”, Dr. Pham Dinh Minh shared more.
Currently, GENTIS has research projects and applications of artificial intelligence as well as bioinformatics in the field of genetic and genetic testing. Specifically, GENTIS is researching and developing AI tools, bioinformatics tools for embryo screening, improving the quality of pre-implantation genetic testing for embryos, and non-invasive prenatal screening NIPT.
Technological autonomy will help improve testing efficiency, optimize testing, improve testing quality, and use Vietnamese data. At the same time, it can help reduce testing costs, as well as bring different testing packages and testing features into GENTIS's current testing packages and testing services.
            [content_more] => 
            [meta_title] => Dr. Pham Dinh Minh reported at the 7th Tzu Chi - Academia Sinica Biomedical Conference
            [meta_description] => On March 8, 2025, Dr. Pham Dinh Minh gave a report at the 7th Tzu Chi - Academia Sinica Biomedical Conference at Tzu Chi University, Hualien, Taiwan.
            [meta_keyword] => gentis,Ai
            [thumbnail_alt] => 
            [post_id] => 1284
            [category_id] => 4
        )

    [5] => stdClass Object
        (
            [id] => 1283
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 6fdf64481b82aadcf393.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-03-11
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-03-11 10:47:49
            [updated_time] => 2025-03-12 15:11:13
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => https://gentis.com.vn/tin-tuc-c4/xet-nghiem-sperm-dna-giai-phap-hieu-qua-giup-bac-si-chan-doan-vo-sinh-nam-d1283
            [title] => Sperm DNA Test - An effective solution to help doctors diagnose male infertility
            [description] => In recent years, infertility has been increasing and tends to be younger in the age of the disease. Many statistics show that the cause of infertility due to men is about 40%, equivalent to the infertility rate in women. Therefore, Sperm DNA is considered an important test for doctors in diagnosing and developing the best treatment regimen for infertile men.
            [content] => 
What is Sperm DNA test?
Sperm DNA is a test that quantifies the rate of broken sperm DNA based on the color change of the dye through the flow cytometry system (Analyzing up to 10,000 sperm). Therefore, Sperm DNA is used as an important additional test in predicting male fertility, supporting the determination of the cause of infertility.

GENTIS's Sperm DNA test helps doctors comprehensively assess the patient's sperm quality
This test helps doctors better screen for cases of unexplained infertility. From there, they can orient appropriate intervention treatment (choosing assisted reproductive methods) to shorten time, costs and increase the chance of having children for couples.
The significance of Sperm DNA testing for male doctors
In an interview, Associate Professor, Dr. Le Minh Tam (Hue University of Medicine and Pharmacy) said: “Male infertility is a matter of great concern recently. For a long time, the methods of assessing male infertility were mainly based on semen analysis. However, the semen analysis method only shows the quantity, mobility density, survival rate... but does not show the internal nature of the sperm. Therefore, tests that describe the nature of the internal nature of the sperm are very meaningful”.
Associate Professor, Dr. Nguyen Quang (President of the Vietnamese Society for Sexual Medicine) shared: “Testing for male infertility is very important. It helps male doctors know the specific causes of male infertility, thereby having a specific direction for treatment for patients”.
Understanding this, GENTIS has researched and launched the Sperm DNA test to support a comprehensive assessment of sperm quality. This is an extremely necessary test for male doctors because:

Helps determine the cause of infertility in men in cases where the semen analysis results are normal.
Explains the phenomenon of consecutive miscarriages, unexplained infertility and IVF failure in couples.
Comprehensive assessment of sperm quality through Sperm DNA testing is extremely necessary to predict fertility and have the most appropriate intervention (choosing a reproductive support method).

Who needs to do the Sperm DNA test?
Sperm DNA testing helps determine the cause of male infertility in cases where the semen analysis results are normal
According to GENTIS experts, men should do Sperm DNA testing if they are in the following cases:

Unexplained male infertility or the cause is unclear.
Recurrent miscarriages.
Clinical symptoms of varicocele.
Lifestyle-related risk factors.
Before or after failure of assisted reproductive methods (ART) such as IUI, IVF, ICSI.
Recurrent miscarriages after ICSI.

GENTIS - The most prestigious Sperm DNA testing unit today
In Vietnam, GENTIS is increasingly affirming its pioneering position in the field of genetic analysis of male infertility by researching and developing new tests. Outstanding advantages of Sperm DNA testing at GENTIS are:

Modern technology: Analysis on the Flow cytometry system (analyzing up to 10,000 sperm). The advantages of the Flow cytometry system are stability, accuracy and high performance in Sperm DNA testing
Automated, fast process
Result return time: 24 hours
Cost: Most reasonable, bringing Sperm DNA testing to all men

With ISO standards and working processes along with a team of leading experts in genetics and highly specialized biotechnology, GENTIS is committed to providing customers with quality Sperm DNA testing, affordable prices, and the most professional services. In particular, Sperm DNA testing supports well in diagnosing genetic factors in male infertility, thereby helping doctors to develop appropriate treatment regimens, overcoming infertility in men.
GENTIS is a pioneer in the field of genetic analysis, specializing in providing tests with the highest accuracy
In addition to Sperm DNA, to evaluate and find the cause of male infertility, GENTIS also provides many specialized tests to help doctors provide appropriate treatment. These include Karyotype testing, hormone testing, sperm DNA fragmentation, AZF testing, anti-sperm antibody testing, sperm chromosome aneuploidy testing, STDs testing, etc.
With a team of leading experts in genetics and biotechnology with high professional qualifications and the most modern facilities and technology, GENTIS is committed to providing tests with the highest accuracy. Thereby contributing to realizing the dream of becoming parents of infertile couples.
            [content_more] => 
            [meta_title] => Sperm DNA Test - An effective solution to help doctors diagnose male infertility
            [meta_description] => Sperm DNA is considered an important test for doctors in diagnosing and developing the best treatment regimen for infertile men.
            [meta_keyword] => gentis,sperm dna
            [thumbnail_alt] => 
            [post_id] => 1283
            [category_id] => 4
        )

    [6] => stdClass Object
        (
            [id] => 1281
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => af39d43f63cfdd9184de.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-02-24
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-02-24 09:14:22
            [updated_time] => 2025-03-06 11:18:33
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => https://gentis.com.vn/tin-tuc-c4/me-bau-nao-nen-thuc-hien-xet-nghiem-sang-loc-truoc-sinh-nipt-d1281
            [title] => Which pregnant women should do Non-invasive prenatal testing?
            [description] => NIPT (Non-invasive prenatal testing) is a method of prenatal screening for pregnant women before giving birth. This prenatal screening method is often chosen because of its non-invasive advantages, helping to detect many congenital malformations in the fetus early, thereby helping pregnant women to manage their pregnancy effectively.
            [content] => 
Who is NIPT suitable for?
With the common mentality of pregnant women being worried about the development and wanting the best care for the fetus, pregnant women always want to look for prenatal testing methods to check the health of the fetus. NIPT testing is recommended for pregnant women in the first 3 months and the middle 3 months of pregnancy, especially for those at high risk:

Pregnant women over 35 years old
According to research by experts, the quality of eggs in women after 35 years old decreases, directly affecting the embryo. Therefore, the fetus is at high risk of chromosomal disorders and is at risk of Down's, Edward's, Patau's syndrome...
In addition, women over 35 years old are often prone to problems such as uterine fibroids, endometriosis... when pregnant, their health declines, hormonal changes make the disease worse, leading to an increased risk of fetal malformations.

Family history of genetic diseases
Studies show that fetal malformations can be passed down from parents to children. If the family has parents-in-law, parents-in-law, or siblings with genetic diseases, the fetus is at high risk of malformations. Although there is no exact research on the percentage, pregnant mothers should also be screened before birth, especially by performing NIPT testing to be able to take good care of the fetus.
Pregnant women who undergo assisted reproductive techniques
The risk of birth defects in children born through artificial insemination is much higher than in children born naturally, even when maternal factors are controlled. Therefore, mothers who undergo this method are advised by doctors to use the NIPT test method.
Biochemical and ultrasound results - high-risk nuchal translucency measurement
History of pregnancy with malformations, unexplained stillbirths or giving birth to children with congenital malformations
Steps to perform NIPT testing

Step 1: Get advice from a doctor
Before taking a sample, the pregnant woman will be informed about the basic information of the NIPT test. Depending on the condition and finances of the pregnant woman, the doctor will advise on appropriate packages. Accompanying pregnant mothers on the path to reproductive health care, GENTIS provides a variety of NIPT prenatal screening service packages

 Genbasic

- Detects aneuploidy on 3 common chromosomes: Down, Patau, Edward
- Applicable for single and twin pregnancies
- Time to return results: 4 - 5 days

 Genbasic Plus

- Detects 5 syndromes: Edwards, Patau, Down, Turner (XO), Klinefelter (XXY)
- Applicable for single and twin pregnancies
- Time to return results: 4 - 5 days

 GenEva

- Detects 8 syndromes: Edwards, Patau, Down, Turner (XO), Klinefelter (XXY), trisomy (XXX), Jacobs (XYY) and detects quantitative abnormalities on all remaining chromosomes
- Applicable for single and twin pregnancies
- Time to return results: 4 - 5 days

 GenEva Plus

- Detects all all types of abnormalities in the GenEva package. At the same time, the package also detects 86 microdeletion mutations
- Applicable for single and twin pregnancies
- Time to return results: 4 - 5 days
Step 2: Take blood for NIPT screening test
Take 7-10ml of blood from the pregnant woman's arm vein for testing.
Step 3: Transfer the blood sample to the GENTIS testing center for analysis.
Step 4: Receive results after 4 - 5 days from the date of sample collection.
Step 5: After receiving the results, the doctor will analyze and advise on appropriate fetal care methods, especially in cases of genetic diseases.
Advantages of performing NIPT testing at GENTIS

High accuracy
NIPT testing is considered more accurate than traditional screening. NIPT prenatal screening is based on DNA genetic material, so it is not affected by environmental factors. In addition, the method is also performed by analyzing the new generation gene sequencing algorithm with a high-tech equipment system with an accuracy rate of over 99%.
Fast results
The test result return time is about 4 - 5 days after sample collection. The sample analysis time by machine is fast, helping NIPT test return results in the shortest time.
Safe
The test sample is the mother's blood, so the prenatal screening method does not cause any negative effects on both mother and baby. Because the test only takes 7-10ml of the mother's blood to separate extracellular DNA, then sequence the DNA and analyze.
Applicable in many cases
NIPT testing is applicable to cases of pregnant mothers with single, twin, and multiple pregnancies.
Screening and detecting diseases related to abnormal chromosomes is extremely good.
NIPT GENTIS test accompanies parents on the journey to welcome their beloved children. Contact hotline: 1800 2010 to schedule a consultation and NIPT test at GENTIS.
            [content_more] => 
            [meta_title] => Which pregnant women should do Non-invasive prenatal testing?
            [meta_description] => NIPT (Non-invasive prenatal testing) is a method of prenatal screening for pregnant women before giving birth.
            [meta_keyword] => gentis,Nipt
            [thumbnail_alt] => 
            [post_id] => 1281
            [category_id] => 4
        )

    [7] => stdClass Object
        (
            [id] => 1280
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => b1fcf6d2f5e24bbc12f3.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-02-19
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-02-19 10:58:57
            [updated_time] => 2025-03-21 15:13:16
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => https://gentis.com.vn/tin-tuc-c4/gentis-ra-mat-2-goi-xet-nghiem-phan-tich-di-truyen-truoc-chuyen-phoi-moi-pgt-next-va-pgt-upgrade-d1280
            [title] => GENTIS launches 2 new test packages: PGT NEXT and PGT UPGRADE
            [description] => With the pioneering advantage in applying genetic and genetic testing in assisted reproduction, GENTIS constantly strives to improve and launch new expanded pre-implantation genetic testing packages: PGT NEXT and PGT UPGRADE. These are two superior in-depth integrated tests with many outstanding advantages.
            [content] => 

PGT NEXT
PGT NEXT is a pre-implantation genetic analysis test that can detect aneuploidy on 24 chromosomes, chromosomal abnormalities, and chromosomal deletions. It can also detect embryos with polyploidy or haploidy. This helps avoid transferring polyploid/haploidy abnormal embryos, and avoid wasting euploid embryos with fertilization abnormalities (0PN, 1PN, and 2.1/3PN). In addition, the PGT NEXT test also supports the provision of genetic information for embryo selection before embryo transfer. The combination of NGS whole genome sequencing with SNP analysis improves the resolution of genetic screening for polyploidy.This method allows for the identification of haploid and polyploid chromosome sets, increasing the number of healthy euploid embryos available for transfer by accurately detecting true diploid embryos among abnormally fertilized embryos (0PN, 1PN, 2.1PN, 3PN). Additionally, SNP analysis ensures precise identification of whether the tested embryo is genetically related to other embryos in the same cohort, thereby reducing the risk of sample mix-ups due to procedural or handling errors.


 Detection range:

- Aneuploidy of all 24 chromosomes
- Chromosomal structural abnormalities (addition, deletion)
- Detection of embryos with polyploidy or haploid abnormalities.

 Method: Whole genome sequencing and target marker sequencing on next-generation sequencing machine NGS.
 Sample used: Day 5 embryo biopsy sample
 Time to return results: 3 – 4 weeks

PGT UPGRADE
PGT UPGRADE is a pre-implantation genetic analysis test that can detect aneuploidy on 24 chromosomes, additional abnormalities, chromosomal deletions with a size of over 5 Mb, especially capable of detecting embryos carrying balanced translocations inherited from the parents. Chromosomal translocations are structural abnormalities of chromosomes caused by the rearrangement of large segments between non-homologous chromosomes. There are two types of translocations: balanced (no loss of genetic material) and unbalanced (loss or extra genetic material, such as aneuploidy). When both the father and mother carry balanced translocations, approximately 60% of gametes will carry unbalanced translocations, leading to embryos with chromosomal abnormalities. This is also a common cause of repeated implantation failure, recurrent miscarriage, and birth defects. PGT UPGRADE test helps to select euploid embryos for parents carrying balanced translocations to increase the chance of having a healthy baby. In addition, PGT UPGRADE also supports providing genetic information for the embryo selection process before embryo transfer.
Performing PGTest testing can select genetically good quality embryos to increase the chance of pregnancy when performing in vitro fertilization (IVF), helping to increase the chance of the child being born healthy, without the screened genetic abnormalities.


 Detection range:

- Aneuploidy of all 24 chromosomes
- Chromosomal structural abnormalities (addition, deletion) larger than 5 Mb
- Detection of embryos carrying balanced genetic translocations inherited from parents

 Method: Next generation sequencing NGS (Illumina) and analysis of sequencing results using specialized bioinformatics software
 Samples used:

- Parental samples (2-3 ml whole blood in EDTA anticoagulant tubes) and balanced translocation test results.
- Day 5 embryo biopsy sample

 Time to return results: 12 - 14 days

Meaning of PGT NEXT and PGT UPGRADE tests
Preimplantation Genetic Testing (PGT) is a specialized technique to identify genetic abnormalities in embryos created through in vitro fertilization (IVF/ICSI). Preimplantation genetic testing offers the following benefits:
Detecting genetic abnormalities in embryos
PGT helps identify abnormalities in chromosome number (PGT-A) or specific gene mutations (PGT-M), thereby reducing the risk of passing on genetic diseases to the next generation.
Increase IVF success rate
Selecting healthy embryos with normal genes improves implantation rates, increases the chance of pregnancy, and reduces the risk of miscarriage.
Support for optimal embryo selection
Ensuring that only embryos that do not carry genetic diseases or genetic abnormalities are transferred into the uterus increases the chances of having a healthy baby.
Advanced and modern technology
Illumina's next-generation sequencing technology (NGS) with >99% accuracy on target markers and specialized bioinformatics software is the technological standard for PGT testing, increasing the accuracy and sensitivity of the test.
Currently, preimplantation genetic testing (PGT) packages can be performed at a number of hospitals and reproductive support centers in Vietnam. Among them, GENTIS is a pioneer in performing PGT testing packages accurately and professionally.
In particular, GENTIS has a system of high-tech machinery and a team of experienced professionals, where infertile couples put their trust when performing difficult tests. Before doing the screening test, customers will be given genetic counseling and detailed information about the test. Through PGT testing packages, GENTIS hopes to support doctors and infertile couples to quickly find their beloved children, as well as give birth to healthy children, bringing happiness to families nationwide.
            [content_more] => 
            [meta_title] => GENTIS launches 2 new test packages: PGT NEXT and PGT UPGRADE
            [meta_description] => GENTIS constantly strives to improve and launch new expanded pre-implantation genetic testing packages: PGT NEXT and PGT UPGRADE.
            [meta_keyword] => gentis,Pgt,Pgtnext,Pgtupgrade
            [thumbnail_alt] => 
            [post_id] => 1280
            [category_id] => 4
        )

)